ArticleDiscover oncology2025
RNA adenosine modification writers define characteristics of immunity and prognosis in head and neck squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RNA Methylation in Cancer Metabolism: from Mechanisms to Therapeutic Opportunities.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo identify potential roles of RNA modification patterns in immunotherapy and prognosis in head and neck squamous cell carcinoma (HNSCC).
methodsWe performed a multiomics analysis of 26 "writers" from four major adenine RNA modifications in 866 HNSCC samples from 3 datasets. We identified two distinct RNA modification patterns using unsupervised clustering of 13 RNA modification writers related to prognosis, and compared biological characteristics like immune cell infiltration, stemness, TME and patient prognosis between patterns. The RNA modification score (RMscore) model was constructed to quantify the RNA modification-related subtypes of individual tumors.
resultsThe RMcluster A had a longer median overall survival (OS) than RMcluster B (5.40 vs. 3.82 years, p = 0.017). RMcluster A had higher levels of immune cells infiltration. RMscore was an independent prognostic factor for HNSCC patients. The median OS was 5.04 years (low RMscore) vs. 2.99 years (high RMscore) (p = 0.012). The expression of immune cell infiltrated was significantly enhanced in patients with low RMscore. Besides, we found that RMscore was positively correlated to IC50 of many chemo or targeted therapy drugs. RMscore was validated to be correlated with the efficacy of immune checkpoints. The objective response rate (CR + PR) of immunotherapy in the low RMscore group was obviously higher than the high RMscore group (26% vs. 5%).
conclusionsRMScore can classify RNA modification patterns and independently predict the prognosis of HNSCC patients. It might contribute to the selection of chemo or targeted drugs in HNSCC and predict the efficacy of immune checkpoints.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.